Hematologic Oncology

William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

In the CALL-0603 study of 44 patients with first marrow-relapsed childhood acute lymphoblastic leukemia, the second complete remission rate was 72.7% for a chemotherapy regimen that included a reduced dose of idarubicin.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia.

The Japanese Ministry of Health, Labor and Welfare has approved the use of daratumumab (Darzalex) for the treatment of adults with relapsed/refractory multiple myeloma.

The FDA has awarded brentuximab vedotin (Adcetris) a breakthrough therapy designation for the first-line treatment of patients with classical Hodgkin lymphoma.

Chimeric antigen receptor T-cell therapy for hematological malignancies took a huge step forward this summer with the FDA approval of Novartis

Harry Erba, MD, PhD, reflects on the 4 approvals and their effect on the treatment of AML moving forward.

Guy Young, MD, discussed the use of anticoagulants in managing thromboembolic events in pediatric cancer.

Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.

Some patients with mantle cell lymphoma can delay treatment without experiencing negative outcomes, according to findings from a population-based study.

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses the occurrence of thromboembolic events in pediatric cancer.

Tisagenlecleucel (Kymriah) induced a complete remission with complete or incomplete hematologic recovery in 83% of pediatric, adolescent, and young adult patients with acute lymphoblastic lymphoma.

The effort to improve outcomes in pediatric acute lymphoblastic leukemia should follow insight provided by next-generation sequencing and appropriate use of minimal residual disease criteria.

The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia and advanced systemic mastocytosis.

Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.

In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.

The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

A 15 mg/kg dose of rabbit anti-T-lymphocyte globulin was associated with similar graft-vs-host-disease, less nonrelapse mortality, and less disease recurrence compared with a 30 mg/kg dose for children with hematological malignancies.

The FDA has granted an accelerated approval to copanlisib (Aliqopa) as a treatment for patients with relapsed follicular lymphoma who have received at least 2 least prior systemic therapies.

Administering high-dose cytarabine to children with myeloid leukemia of Down syndrome during the second chemotherapy induction cycle resulted in improved event-free survival and overall survival compared to results observed in previous research studies.